Full Year Results 

Scapa comes unstuck on exceptionals

Scapa comes unstuck on exceptionals

It is approaching 12 months since Scapa (SCPA) launched legal action against medical technology group ConvaTec (CTEC), formerly Scapa’s biggest healthcare customer, over its decision to exit a contract worth $30m (£24m). The matter remains unresolved, and the impact of the lost contract sat among a raft of exceptional charges amounting to £68.4m for the year. Once one-offs are disregarded, adjusted operating profit was 29 per cent down on the prior year.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now